These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28530802)

  • 1. Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.
    Felts AS; Rodriguez AL; Blobaum AL; Morrison RD; Bates BS; Thompson Gray A; Rook JM; Tantawy MN; Byers FW; Chang S; Venable DF; Luscombe VB; Tamagnan GD; Niswender CM; Daniels JS; Jones CK; Conn PJ; Lindsley CW; Emmitte KA
    J Med Chem; 2017 Jun; 60(12):5072-5085. PubMed ID: 28530802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative allosteric modulation of metabotropic glutamate receptor 5 attenuates alcohol self-administration in baboons.
    Salling MC; Grassetti A; Ferrera VP; Martinez D; Foltin RW
    Pharmacol Biochem Behav; 2021 Sep; 208():173227. PubMed ID: 34224733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy.
    Nickols HH; Yuh JP; Gregory KJ; Morrison RD; Bates BS; Stauffer SR; Emmitte KA; Bubser M; Peng W; Nedelcovych MT; Thompson A; Lv X; Xiang Z; Daniels JS; Niswender CM; Lindsley CW; Jones CK; Conn PJ
    J Pharmacol Exp Ther; 2016 Jan; 356(1):123-36. PubMed ID: 26503377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254).
    Turlington M; Noetzel MJ; Chun A; Zhou Y; Gogliotti RD; Nguyen ED; Gregory KJ; Vinson PN; Rook JM; Gogi KK; Xiang Z; Bridges TM; Daniels JS; Jones C; Niswender CM; Meiler J; Conn PJ; Lindsley CW; Stauffer SR
    J Med Chem; 2013 Oct; 56(20):7976-96. PubMed ID: 24050755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Acting at Site Distinct from 2-Methyl-6-(phenylethynyl)-pyridine Binding.
    Butkiewicz M; Rodriguez AL; Rainey SE; Wieting J; Luscombe VB; Stauffer SR; Lindsley CW; Conn PJ; Meiler J
    ACS Chem Neurosci; 2019 Aug; 10(8):3427-3436. PubMed ID: 31132237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding Exposure-Receptor Occupancy Relationships for Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators across a Range of Preclinical and Clinical Studies.
    Bennett KA; Sergeev E; MacSweeney CP; Bakker G; Cooper AE
    J Pharmacol Exp Ther; 2021 Apr; 377(1):157-168. PubMed ID: 33541889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.
    Felts AS; Bollinger KA; Brassard CJ; Rodriguez AL; Morrison RD; Scott Daniels J; Blobaum AL; Niswender CM; Jones CK; Conn PJ; Emmitte KA; Lindsley CW
    Bioorg Med Chem Lett; 2019 Jan; 29(1):47-50. PubMed ID: 30446311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.
    Felts AS; Rodriguez AL; Morrison RD; Blobaum AL; Byers FW; Daniels JS; Niswender CM; Conn PJ; Lindsley CW; Emmitte KA
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1679-1685. PubMed ID: 29705142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species-Specific Involvement of Aldehyde Oxidase and Xanthine Oxidase in the Metabolism of the Pyrimidine-Containing mGlu
    Crouch RD; Blobaum AL; Felts AS; Conn PJ; Lindsley CW
    Drug Metab Dispos; 2017 Dec; 45(12):1245-1259. PubMed ID: 28939686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity.
    Rook JM; Noetzel MJ; Pouliot WA; Bridges TM; Vinson PN; Cho HP; Zhou Y; Gogliotti RD; Manka JT; Gregory KJ; Stauffer SR; Dudek FE; Xiang Z; Niswender CM; Daniels JS; Jones CK; Lindsley CW; Conn PJ
    Biol Psychiatry; 2013 Mar; 73(6):501-9. PubMed ID: 23140665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro binding of a radio-labeled positive allosteric modulator for metabotropic glutamate receptor subtype 5.
    Zysk JR; Spear N; Fieles W; Stein MM; Sygowski LS; King MM; Hoesch V; Hastings R; Brockel B; Do M; Ström P; Gadient R; Chhajlani V; Elmore CS; Maier DL
    Synapse; 2013 Mar; 67(3):135-44. PubMed ID: 23150216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabotropic glutamate receptor 5 (mGlu
    Hellyer SD; Albold S; Sengmany K; Singh J; Leach K; Gregory KJ
    J Neurochem; 2019 Nov; 151(3):301-315. PubMed ID: 31376155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology.
    Sengmany K; Hellyer SD; Albold S; Wang T; Conn PJ; May LT; Christopoulos A; Leach K; Gregory KJ
    Neuropharmacology; 2019 May; 149():83-96. PubMed ID: 30763654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.
    Felts AS; Rodriguez AL; Morrison RD; Bollinger KA; Venable DF; Blobaum AL; Byers FW; Thompson Gray A; Daniels JS; Niswender CM; Jones CK; Conn PJ; Lindsley CW; Emmitte KA
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4858-4866. PubMed ID: 28958625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.
    Bates BS; Rodriguez AL; Felts AS; Morrison RD; Venable DF; Blobaum AL; Byers FW; Lawson KP; Daniels JS; Niswender CM; Jones CK; Conn PJ; Lindsley CW; Emmitte KA
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3307-14. PubMed ID: 24969015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulator.
    Hao J; Dehlinger V; Fivush AM; Rudyk HC; Britton TC; Hollinshead SP; Vokits BP; Clark BP; Henry SS; Massey SM; Peng L; Dressman BA; Heinz BA; Roberts EF; Bracey-Walker MR; Swanson S; Catlow JT; Love PL; Tepool AD; Peters SC; Simmons RM; Iyengar S; McKinzie DL; Monn JA
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1249-52. PubMed ID: 23374867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of 4-(2-fluoro-4-[
    Kumata K; Hatori A; Yamasaki T; Zhang Y; Mori W; Fujinaga M; Xie L; Nengaki N; Zhang MR
    Bioorg Med Chem; 2019 Feb; 27(3):483-491. PubMed ID: 30611634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles.
    Rook JM; Tantawy MN; Ansari MS; Felts AS; Stauffer SR; Emmitte KA; Kessler RM; Niswender CM; Daniels JS; Jones CK; Lindsley CW; Conn PJ
    Neuropsychopharmacology; 2015 Feb; 40(3):755-65. PubMed ID: 25241804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator.
    Zhang L; Balan G; Barreiro G; Boscoe BP; Chenard LK; Cianfrogna J; Claffey MM; Chen L; Coffman KJ; Drozda SE; Dunetz JR; Fonseca KR; Galatsis P; Grimwood S; Lazzaro JT; Mancuso JY; Miller EL; Reese MR; Rogers BN; Sakurada I; Skaddan M; Smith DL; Stepan AF; Trapa P; Tuttle JB; Verhoest PR; Walker DP; Wright AS; Zaleska MM; Zasadny K; Shaffer CL
    J Med Chem; 2014 Feb; 57(3):861-77. PubMed ID: 24392688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
    Parmentier-Batteur S; Hutson PH; Menzel K; Uslaner JM; Mattson BA; O'Brien JA; Magliaro BC; Forest T; Stump CA; Tynebor RM; Anthony NJ; Tucker TJ; Zhang XF; Gomez R; Huszar SL; Lambeng N; Fauré H; Le Poul E; Poli S; Rosahl TW; Rocher JP; Hargreaves R; Williams TM
    Neuropharmacology; 2014 Jul; 82():161-73. PubMed ID: 23291536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.